Business
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates,
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting is being held on March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta. \n\"We're excited to showcase our promising immuno-oncology pipeline, which is strategically developed to target multiple points in the cancer immunity cycle to amplify the body's ability to fight tumor cells,\" said Jonathan Zalevsky, Ph.D., Chief Scientific Officer at Nektar. \"The preclinical studies presented at AACR 2019, by both Nektar scientists and our collaborators highlight the promise of targeting the IL-2 and IL-15 pathways to activate the immune system to induce durable anti-tumor responses in combination with complementary mechanisms such as personalized T cell vaccines and tumor-directed antibody therapies. We plan to explore these combinations further and look forward to advancing them into the clinic.\"\nDetails of the poster presentations at AACR Annual Meeting 2019 are as follows and each will be available for download at the time of presentation at http://www.nektar.com/science/scientific-posters or by clicking on the links below.\nAbstract #2256/Poster Board #15Title: \"Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models\", Granum, S., et al.Session: Clinical Research - Combination Immunotherapies 1Date: Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. Eastern Time Location: Exhibit Hall B, Poster Section 19\nVB10.NEO and bempegaldesleukin (NKTR-214) worked synergistically to elicit greater breadth and depth of neoantigen-specific T cell responses than each individual treatment. The synergistic effect was observed in both CD4 and CD8 T cells, and most pronounced on CD8 T cell responses, further supporting the combination's potential to induce strong immunogenic CD8+ T cell responses. VB10.NEO in combination with bempegaldesleukin (NKTR-214) and anti-PD-1 induced rapid, complete and durable tumor r...